celecoxib has been researched along with Diabetes Mellitus, Type 2 in 6 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin was administered orally every day to rats with OA." | 5.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "Acute interstitial nephritis is a well-described complication of therapy with nonselective nonsteroidal anti-inflammatory drugs." | 5.31 | Celecoxib-induced acute interstitial nephritis. ( Henao, J; Hewan-Lowe, K; Hisamuddin, I; Nzerue, CM; Vasandani, G, 2002) |
| " Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis." | 5.11 | The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. ( Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N, 2005) |
| "Metformin was administered orally every day to rats with OA." | 1.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| " When treating Bartter's syndrome, it is also prudent to remember that the long-term use of nonsteroidal anti-inflammatory drugs and potassium-sparing diuretics may result in serious adverse reactions." | 1.35 | Bartter's syndrome with type 2 diabetes mellitus. ( Lee, SP; See, TT, 2009) |
| "Acute interstitial nephritis is a well-described complication of therapy with nonselective nonsteroidal anti-inflammatory drugs." | 1.31 | Celecoxib-induced acute interstitial nephritis. ( Henao, J; Hewan-Lowe, K; Hisamuddin, I; Nzerue, CM; Vasandani, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Na, HS | 1 |
| Kwon, JY | 1 |
| Lee, SY | 1 |
| Lee, SH | 1 |
| Lee, AR | 1 |
| Woo, JS | 1 |
| Jung, K | 1 |
| Cho, KH | 1 |
| Choi, JW | 1 |
| Lee, DH | 1 |
| Min, HK | 1 |
| Park, SH | 1 |
| Kim, SJ | 1 |
| Cho, ML | 1 |
| Tian, F | 1 |
| Zhang, YJ | 1 |
| Li, Y | 1 |
| Xie, Y | 1 |
| See, TT | 1 |
| Lee, SP | 1 |
| Alper, AB | 1 |
| Meleg-Smith, S | 1 |
| Krane, NK | 1 |
| Sowers, JR | 1 |
| White, WB | 1 |
| Pitt, B | 1 |
| Whelton, A | 1 |
| Simon, LS | 1 |
| Winer, N | 1 |
| Kivitz, A | 1 |
| van Ingen, H | 1 |
| Brabant, T | 1 |
| Fort, JG | 1 |
| Henao, J | 1 |
| Hisamuddin, I | 1 |
| Nzerue, CM | 1 |
| Vasandani, G | 1 |
| Hewan-Lowe, K | 1 |
1 trial available for celecoxib and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determi | 2005 |
5 other studies available for celecoxib and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway.
Topics: Animals; Arthritis, Experimental; Celecoxib; Chondrocytes; Diabetes Mellitus, Type 2; Disease Models | 2021 |
Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression.
Topics: Animals; Biomarkers; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Ty | 2014 |
Bartter's syndrome with type 2 diabetes mellitus.
Topics: Adult; Bartter Syndrome; Celecoxib; Diabetes Mellitus, Type 2; Female; Humans; Indomethacin; Pyrazol | 2009 |
Nephrotic syndrome and interstitial nephritis associated with celecoxib.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cycl | 2002 |
Celecoxib-induced acute interstitial nephritis.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibi | 2002 |